When standard therapies for generalized myasthenia gravis (gMG) are no longer sufficient, where do international patients look next?
China’s regulatory landscape has recently expanded to include highly targeted biologic approvals, such as FcRn inhibitors and B-cell pathways. However, NMPA approval doesn't guarantee immediate access—overseas patients face complex administrative hurdles, from exact biomarker matching to navigating localized hospital formularies.
As a specialized medical concierge provider, MedBridgeNZ does not provide medical treatment; instead, we bridge the logistical gap. We help international patients assess their options for Medical Tourism China by coordinating expert medical record translation, remote institutional review, and on-the-ground administrative logistics.
Explore our latest guide on navigating the administrative pathway for refractory gMG in China: What Are the Options for Refractory Myasthenia Gravis Treatment in China? Exploring FcRn and B-Cell Pathways